Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Increases By 18.8%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 13,900 shares, an increase of 18.8% from the November 15th total of 11,700 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 48,600 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Catalina Capital Group LLC bought a new position in Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 17,819 shares of the company’s stock, valued at approximately $25,000. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Trading Up 11.3 %

Shares of BRNS stock traded up $0.09 on Friday, reaching $0.91. The company’s stock had a trading volume of 20,486 shares, compared to its average volume of 80,126. The stock’s fifty day simple moving average is $1.17 and its 200-day simple moving average is $1.34. Barinthus Biotherapeutics has a 1 year low of $0.80 and a 1 year high of $4.16. The company has a market capitalization of $36.71 million, a price-to-earnings ratio of -0.61 and a beta of -0.73.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.23. The business had revenue of $14.97 million during the quarter. During the same period in the prior year, the firm earned ($0.37) earnings per share. Equities research analysts forecast that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Barinthus Biotherapeutics in a research report on Tuesday, November 19th.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.